Document Detail


Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients.
MedLine Citation:
PMID:  3667307     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have previously demonstrated a high degree of selective binding of monoclonal antibody (MAb) B72.3 to carcinomas of the colon, ovary, and breast in contrast to normal adult tissues using in vitro assays. In this report we demonstrate selective tumor localization in colorectal cancer patients after intravenously administering 131I-labeled MAb B72.3 IgG. Radiolocalization Indices (RI) (i.e. cpm 131I-labeled MAb per gram of tumor vs cpm per gram of normal tissues), were obtained by direct analyses of biopsy materials. Using an RI of greater than or equal to 3 as a positive localization, tumor lesions in various sites from 17/20 patients scored positive. In eight of these patients, all tumor lesions demonstrated RIs of greater than 3, while in five patients RIs of some lesions were greater than 10 and as high as 30-46. Seventy percent (99/142) of the tumor lesions showed RIs of greater than 3, while only 12 of 210 histologically confirmed normal tissues examined showed RIs of greater than 3. These tissues were either adjacent to the tumor or the draining tumor masses or, as in the case of two patients, was caused by high levels of circulating immune complexes that deposited in the spleen. Positive scintigraphic images (confirmed at surgery) were observed in 14/27 patients. No toxicity or adverse reactions were observed with either MAb. These studies provide absolute quantitative analyses of the actual delivery of radiolabeled MAb to carcinoma lesions vs a wide range of adjacent and distal normal tissues and establishes the means for other diagnostic and potential therapeutic applications of this antibody alone, or in combinations with other monoclonal antibodies.
Authors:
D Colcher; J A Carrasquillo; J M Esteban; P Sugarbaker; J C Reynolds; K Siler; G Bryant; S M Larson; J Schlom
Related Documents :
18482677 - Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
17127167 - Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
8998167 - Tumor imaging with technetium-99m-labeled hydrazinonicotinamide-fab' conjugates.
20403397 - Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnos...
20354907 - Antitumor activity of an adenovirus harboring human il-24 in colon cancer.
15846107 - Regulation of vascular endothelial growth factor (vegf) production and angiogenesis by ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology     Volume:  14     ISSN:  0883-2897     ISO Abbreviation:  Int J Rad Appl Instrum B     Publication Date:  1987  
Date Detail:
Created Date:  1987-12-01     Completed Date:  1987-12-01     Revised Date:  2008-02-21    
Medline Journal Info:
Nlm Unique ID:  8611098     Medline TA:  Int J Rad Appl Instrum B     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  251-62     Citation Subset:  IM    
Affiliation:
Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / diagnostic use*,  metabolism
Colonic Neoplasms / metabolism,  radionuclide imaging*
Humans
Iodine Radioisotopes / diagnostic use*
Neoplasm Metastasis / metabolism,  radionuclide imaging*
Rectal Neoplasms / metabolism,  radionuclide imaging*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Iodine Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic use of 90Y microspheres.
Next Document:  Radiation safety and handling of therapeutic radionuclides.